VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISAL 2019 | The benefits of dual-targeting triplebodies

Georg Fey
ISAL 2019
Acute Myeloid Leukemia Leukemia Antibodies SPM-2

Speaking from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany, Georg Fey, PhD, of the University of Erlangen Nuremberg, Erlangen and Nuremberg, Germany, explains the benefits of dual-targeting triplebodies.

More from Georg Fey

4:24
Triplebody development process
Georg Fey
3:57
Triplebodies for AML: origin, rationale & development
Georg Fey

Related Videos

1:41
Key challenges of using the intestinal microbiome as a biomarker
Melody Smith
1:32
CAR T-cell therapy: the importance of LTFU
Graham Collins
1:44
The future of AML therapy
Andreas Burchert
0:42
Treating pediatric patients with hematological malignancies
Claudia Rössig

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals